In June 2023, BioNTech presented the first human trial data of BNT211 at the American Society of Clinical Oncology (ASCO). BNT211 is a CLDN-6-targeting CAR-T cell therapy in combination with a CLDN6-encoding mRNA vaccine (CARVac). mRNA vaccines stimulate the expansion of CAR-T cells in the patients’ body by inducing the expression of CLDN6 on the surface of antigen-presenting cells, […]
Category Archives: Blog
In 2023…… On May 12th, LaNova announced that AstraZeneca will receive an exclusive global license for LM-305’s research, development, and commercialization. LM-305 is a new pre-clinical stage antibody-drug conjugate (ADC) targeting GPRC5D. LaNova Medicines will receive an immediate payment of $55 million and $545 million in additional development and commercial milestone payments. On May 19th, the clinical trial application for OriCAR-017 […]